Browse KIAA0319

Summary
SymbolKIAA0319
NameKIAA0319
Aliases neuronal migration; DYLX2; Dyslexia-associated protein KIAA0319
Chromosomal Location6p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein Early endosome membrane Single-pass type I membrane protein Note=Low-abundance isoforms lacking the transmembrane domain have been described; these are secreted.
Domain PF02010 REJ domain
Function

Involved in neuronal migration during development of the cerebral neocortex. May function in a cell autonomous and a non-cell autonomous manner and play a role in appropriate adhesion between migrating neurons and radial glial fibers. May also regulate growth and differentiation of dendrites.

> Gene Ontology
 
Biological Process GO:0001764 neuron migration
GO:0010721 negative regulation of cell development
GO:0010975 regulation of neuron projection development
GO:0010977 negative regulation of neuron projection development
GO:0016358 dendrite development
GO:0031345 negative regulation of cell projection organization
GO:0045665 negative regulation of neuron differentiation
GO:0050768 negative regulation of neurogenesis
GO:0050773 regulation of dendrite development
GO:0051961 negative regulation of nervous system development
GO:2000171 negative regulation of dendrite development
Molecular Function -
Cellular Component GO:0005769 early endosome
GO:0010008 endosome membrane
GO:0031901 early endosome membrane
GO:0044440 endosomal part
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-8856825: Cargo recognition for clathrin-mediated endocytosis
R-HSA-8856828: Clathrin-mediated endocytosis
R-HSA-199991: Membrane Trafficking
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolKIAA0319
NameKIAA0319
Aliases neuronal migration; DYLX2; Dyslexia-associated protein KIAA0319
Chromosomal Location6p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between KIAA0319 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolKIAA0319
NameKIAA0319
Aliases neuronal migration; DYLX2; Dyslexia-associated protein KIAA0319
Chromosomal Location6p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of KIAA0319 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolKIAA0319
NameKIAA0319
Aliases neuronal migration; DYLX2; Dyslexia-associated protein KIAA0319
Chromosomal Location6p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of KIAA0319 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2020.745
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0120.992
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.4450.761
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4590.476
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2440.832
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.740.558
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2760.619
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.670.357
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.9030.000625
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of KIAA0319 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.44.13.30.61
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.45.12.30.647
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolKIAA0319
NameKIAA0319
Aliases neuronal migration; DYLX2; Dyslexia-associated protein KIAA0319
Chromosomal Location6p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KIAA0319. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolKIAA0319
NameKIAA0319
Aliases neuronal migration; DYLX2; Dyslexia-associated protein KIAA0319
Chromosomal Location6p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KIAA0319. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KIAA0319.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolKIAA0319
NameKIAA0319
Aliases neuronal migration; DYLX2; Dyslexia-associated protein KIAA0319
Chromosomal Location6p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KIAA0319. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolKIAA0319
NameKIAA0319
Aliases neuronal migration; DYLX2; Dyslexia-associated protein KIAA0319
Chromosomal Location6p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of KIAA0319 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolKIAA0319
NameKIAA0319
Aliases neuronal migration; DYLX2; Dyslexia-associated protein KIAA0319
Chromosomal Location6p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between KIAA0319 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolKIAA0319
NameKIAA0319
Aliases neuronal migration; DYLX2; Dyslexia-associated protein KIAA0319
Chromosomal Location6p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting KIAA0319 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.